Conformation of Repaglinide (cas 108157-52-4): A solvent dependent structure
-
Add time:08/27/2019 Source:sciencedirect.com
Experimental and theoretical conformational study of repaglinide in chloroform and dimethyl sulfoxide was investigated. By applying potential energy scanning (PES) at B3LYP/6-311++g** and B3LYP-D3/6-311++g** level of theory on rotatable single bonds, four stable conformers (R1-R4) were identified. Spin-spin coupling constant values were obtained from a set of 2D NMR spectra (HH COSY, HC HMQC and HC HMBC) and compared to its calculated values. Interestingly, from 1HNMR and 2D-NOESY NMR, it has been found that repaglinide structure is folded in CDCl3 and cause all single bonds to rotate at an extremely slow rate. On the other hand, in DMSO-d6, with strong solvent-solute intermolecular interactions, the single bonds rotate freely. Also, energy barrier and thermodynamic parameters for chair to chair interconversion was measured (13.04 kcal mol−1) in CDCl3 solvent by using temperature dynamic NMR.
We also recommend Trading Suppliers and Manufacturers of Repaglinide (cas 108157-52-4). Pls Click Website Link as below: cas 108157-52-4 suppliers
Prev:Repaglinide (cas 108157-52-4)☆
Next:The first insight into the supramolecular structures of popular drug Repaglinide (cas 108157-52-4): Focus on intermolecular interactions in antidiabetic agents) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- A floating-type dosage form of Repaglinide (cas 108157-52-4) in polycarbonate microspheres08/31/2019
- Development of Repaglinide (cas 108157-52-4) microspheres using novel acetylated starches of bitter and Chinese yams as polymers08/30/2019
- Dual crosslinked pectin–alginate network as sustained release hydrophilic matrix for Repaglinide (cas 108157-52-4)08/29/2019
- The first insight into the supramolecular structures of popular drug Repaglinide (cas 108157-52-4): Focus on intermolecular interactions in antidiabetic agents08/28/2019
- Repaglinide (cas 108157-52-4)☆08/26/2019
- Conformational flexibility and packing plausibility of Repaglinide (cas 108157-52-4) polymorphs08/25/2019
- Identification of Repaglinide (cas 108157-52-4) as a therapeutic drug for glioblastoma multiforme08/24/2019
- Endocrine pharmacologyCharacteristics of Repaglinide (cas 108157-52-4) effects on insulin secretion08/23/2019
- ArticleThe Structural Basis for the Binding of Repaglinide (cas 108157-52-4) to the Pancreatic KATP Channel08/22/2019


